Nephrology

Targeting CD28 and CD154 pathways, dual blockade with belatacept and dazodalibep offers a new mechanistic approach in kidney transplant care.

Stocker discusses the potential for a wearable patch to continuous drug measurement of vancomycin, especially in pediatric patients and outpatient settings.

Experts in nephrology explain the benefits of kidney transplantation, the evolving immunosuppression landscape, and evaluate the risk factors for donors.

MAJESTY, a phase 3 study evaluating obinutuzumab in primary membranous nephropathy, demonstrates positive efficacy and safety.

Experts discuss shifting CKD detection upstream, improving albuminuria screening, and enabling earlier, risk-based intervention.

Stocker discusses findings from a pilot phase trial with clinical insight into a wearable patch for continuous drug measurement of vancomycin.

FLOW/SELECT suggest. GLP-1 receptor agonists may protect kidneys beyond glucose control

The 2025 KDIGO guidelines guide mechanism-driven therapy in IgA nephropathy, highlighting targeted interventions across the 4-hit disease cascade.

Tegoprubart, a CD40L-targeted therapy, may improve long-term kidney transplant outcomes by reducing immune-mediated injury.

2025 KDIGO guidelines reshape IgA nephropathy care with earlier biopsy, tighter proteinuria targets, and personalized treatment strategies.

Eliezer Katz, MD, says investigational anti-CD40L therapy tegoprubart shows promise as a non-calcineurin inhibitor option for adult de novo kidney transplant patients

TACITO phase 2a suggests an improvement in clinical outcomes for patients with mRCC with fecal microbiota transplantation

FDA decisions, KDIGO guidelines, and federal nutrition updates redefine kidney care in January 2026

Obesity is common in CKD and drives hyperfiltration, nephron stress, and progressive kidney injury, according to experts, Kramer and Perkovic, and trial data.

With the acceptance, the FDA has assigned the oral phosphate binder a Prescription Drug User Fee Act target action date of June 29, 2026.

In a 31-center phase 2 trial in 10 countries, apecotrep BI 764198 reduced proteinuria in patients with primary focal segmental glomerulosclerosis.

A scoping review of 18 trials finds psychological, nutritional, and exercise support consistently benefits kidney cancer patients.

The first scoping review of kidney cancer pre/ rehabilitation suggests psychological support outdoes exercise and nutrition.

Tim Pflederer, explains how nephrologists can help patients with CKD and ESKD navigate the 2025–2030 Dietary Guidelines, including managing protein, potassium, and phosphorus intake.

Updated federal guidelines highlight protein intake, with Tim Pflederer emphasizing the importance of individualized nutrition strategies for CKD patients

Andrew Vissing shares his clinical perspective and strategies to mitigate gaps in care and management for young adults with glomerular disease.

New CureGN findings and an interview with Andrew Vissing, MD, highlight distinct glomerular disease outcomes in adolescents and young adults compared with pediatric and adult patients

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

Post hoc MODIFY data showed no significant eGFR or UACR benefit with lucerastat, though exploratory signals appeared in patients with baseline renal impairment.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clearances, in this week’s essential news roundup.